SOMAí Pharmaceuticals May 2023 Newsletter
Newsletter?- May 2023
SOMAí has been highly active as we continue to make significant strides toward our highly anticipated product launch scheduled for the latter half of 2023. We are pleased to announce the?complete roll-out?of our?oral drops, catering to a wide range of patient's needs. We will also?introduce THC and CBD distillate APIs, further expanding our product range. Lastly, we are excited to announce that we have made significant progress toward?launching our Vape Oils, bringing us one step closer to making them available on the market.
In May, SOMAí launched?stability testing?for our medical cannabis Vape Oils. With rigorous testing and advanced analysis, we ensure our products potency, effectiveness, and consistent performance over time. We are proud to offer our diverse range of Vape Oils in numerous markets, allowing patients worldwide to benefit from our exceptional treatments. Our product line includes?1ml and 0.5ml?variants, as well as versions infused with carefully crafted terpene mixes, and two different formats: a Finished Product format and a Magisterial Preparation format to cater to all medical cannabis markets. Explore the possibilities of our medical cannabis Vape Oils and unlock new avenues for growth and success in this dynamic industry.
SOMAí is excited to announce our?partnership with Cosma Cannabis, a respected Polish distributor of high-quality medical-grade cannabis products. This collaboration opens doors for us to enter Poland's fast-emerging medical cannabis markets. Under the agreement, SOMAí will supply Cosma Cannabis with a diverse range of premium medical cannabis products for importation and distribution across the country. With a sales value of 1,000,000 euros, this partnership is an important step towards our 2024 goals of expanding and developing the medical cannabis sector in Poland.
Michael Sassano , the CEO and Chairman of SOMAí Pharmaceuticals expressed his pride in being chosen by Cosma as their preferred manufacturer to enter the Polish market. Being one of the first manufacturers in a large market with positive regulatory reforms must have good partners like Cosma that can effectively educate and represent our current and future product offerings.” - he concludes.
Apart from that, SOMAí signed a five-year?agreement with Clever Leaves ?Holdings Inc.?to supply Portugal with EU-GMP-certified CBD extracts from Colombia in May. With the first shipments already completed, enabling SOMAí to further process the pharmaceutical-grade APIs and CBD extracts into finished products for patients across Europe as part of their mission to become one of the largest producers in Europe's medical cannabis market and develop innovative dosage forms for consistent delivery of active ingredients to patients.
Our facility?expansion's second phase?is underway. This expansion aims to enhance our capabilities, increase our product portfolio and provide more clean room production space. As part of this phase, we are adding a soft gel capsule production area, introducing sublingual and transdermal tabs production, establishing a specialized room for vape cartridge and syringe filling, and incorporating two new primary and secondary packaging lines. Additionally, we are adding?high-speed bottling?capabilities to enhance our production efficiency and meet growing market demands.
We were thrilled to participate as a?Silver Sponsor?at the? Cannabis Europa ?event in London at the start of May. We're passionate about leveraging technology to drive innovation in the industry, and we were delighted to connect with industry professionals and attendees, discuss the future of cannabis, and showcase our innovative solutions.
In May, we received?final approval from Infarmed, a Government agency responsible for evaluating, authorizing, regulating, and controlling human medicines and health products.?The next step is the PSP inspection of our facility, set for the 31st of May, which will complete the evaluation journey of us receiving a GMP certificate.
SOMAí?- June highlights:?
We will continue working on organizing the?Open Doors Day event, which will take place on July 2, 2023. This event provides a chance to tour our facility, meet SOMAí's Founders and other team members, and learn about the products and services offered by our company. Only a few spots are left, so if you want to participate,?please?fill in the form ?today.
We are excited to announce that?SOMAí?Pharmaceuticals will?participate?in the international cannabis business conference? InternationalCBC , which will take place on 29-30 June in Berlin. Our CEO and Founder,?Michael Sassano, will be a?speaker?at the?"Cannabis Biotech"?panel, where esteemed experts delve into the most recent innovations in cannabis biotechnology, discussing the opportunities and obstacles accompanying conducting research in this dynamic and captivating field. We look forward to meeting everyone at our #184 stand and engaging in discussions about the future of the medical cannabis industry.
We expect to complete the GMP inspection journey in June and receive the certification.?Receiving GMP certification?will mark a significant milestone for us. It demonstrates our commitment to maintaining our manufacturing processes' highest quality and safety standards. The certification enhances our credibility, instills confidence in our stakeholders, and opens up opportunities for growth and collaboration in the industry. This achievement validates our dedication to excellence and delivering safe, high-quality products.
Check our latest useful links:
You can get information about SOMAí products and services in the?Product Catalogue
We are also thrilled to announce that we have done?extensive research on SOMAí Pharmaceuticals. You can read the full research here: SOMAí Equity Research
Latest articles from our CEO, Michael Sassano